About northwest biotherapeutics - NWBO
Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.
NWBO At a Glance
Northwest Biotherapeutics, Inc.
4800 Montgomery Lane
Bethesda, Maryland 20814
| Phone | 1-240-497-9024 | Revenue | 1.93M | |
| Industry | Pharmaceuticals: Major | Net Income | -62,599,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 14.795% | |
| Fiscal Year-end | 12 / 2024 | Employees | 22 | |
| View SEC Filings |
NWBO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 406.083 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -15.745 |
| Enterprise Value to Sales | 438.253 |
| Total Debt to Enterprise Value | 0.054 |
NWBO Efficiency
| Revenue/Employee | 87,818.182 |
| Income Per Employee | -2,845,409.091 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.065 |
NWBO Liquidity
| Current Ratio | 0.091 |
| Quick Ratio | 0.091 |
| Cash Ratio | 0.047 |
NWBO Profitability
| Gross Margin | 10.30 |
| Operating Margin | -2,873.085 |
| Pretax Margin | -3,240.114 |
| Net Margin | -3,240.114 |
| Return on Assets | -210.963 |
| Return on Equity | N/A |
| Return on Total Capital | 4,420.833 |
| Return on Invested Capital | N/A |
NWBO Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -3,217.514 |
| Total Debt to Total Assets | 163.04 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -1,749.011 |